News & publications
Stay in the know about the science, events, and breakthroughs happening at Riboscience.
News
MAY 30, 2025 | PRESS RELEASE
Riboscience Announces Successful Completion of Phase 1a Dose Escalation for RBS2418, a New Anti-Cancer Immunotherapy
MAY 29, 2024 | PUBLICATION
Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab
OCTOBER 20, 2023 | PRESS RELEASE
Riboscience ESMO presentation highlights safety, PK, PD, and efficacy data from the first 19 patients of the ENPP1 inhibitor RBS2418 Phase 1 study
DECEMBER 7, 2022 | PRESS RELEASE
Riboscience ESMO I/O Presentations Highlight RBS2418 Phase 1 Study Design and the First Human Data From the Evaluation of an ENPP1 Inhibitor for Immune Activation
JUNE 20, 2022 | PRESS RELEASE
First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer